merck immuno oncolog vaccin platform
posit long-term growth
updat forecast estim oct
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim oct
price data oct
rate updat oct
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
merck combin wide line-up high-margin drug
pipelin new drug ensur strong return invest
capit long term merck worst
patent cliff remov heighten gener
competit compani experienc past year
sever year moder research develop
product merck drug develop strategi yield
merck new product mitig gener competit
offset recent major patent loss particular keytruda
cancer repres key blockbust multi-billion-dollar
potenti hold first-mov advantag one largest
cancer indic non-smal cell lung cancer also expect
new cancer drug combin propel merck overal
drug sale howev expect intens competit cancer
market sever competit drug like report import
clinic data headwind includ
gener competit notabl cardiovascular drug zetia
vytorin like creat drag overal growth
migrain safeti question end
sever year mix result merck product
improv compani shift toward area unmet
medic need owe side effect lack compel efficaci
merck experienc major setback cardiovascular diseas
drug anacetrapib tredapt rolofyllin tra along
develop osteoporosi drug odanacatib despit
setback merck solid success includ success
launch drug keytruda oncolog follow
success merck shift focu toward area unmet medic
need specialty-car area keytruda lead new
direct expect keytruda leadership non-smal cell lung
cancer key driver growth compani next
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
merck make pharmaceut product treat sever condit
number therapeut area includ cardiovascular diseas asthma
cancer infect within cancer firm immuno-oncolog platform
grow major contributor overal sale compani also
substanti vaccin busi treatment prevent hepat
pediatr diseas well hpv shingl addit merck sell
anim health-rel drug geograph perspect close
firm sale gener unit state
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
increas fair valu estim
per share larg base increas project cancer
drug keytruda lynparza well hpv vaccin
gardasil expect keytruda gain lion share
late stage non-smal cell lung cancer nsclc market
well close adjuv nsclc market overal
continu expect steadi long-term
growth partli driven solid outlook cancer drug
keytruda lesser extent strong outlook hpv
vaccin gardasil larg intern market keytruda
key merck valuat expect leader
immuno-oncolog market expect drug
reach peak sale billion larg base strong
efficaci sever cancer type includ lung head
neck melanoma sever cancer indic
look entir compani next five year
expect merck post annual top-lin growth
new drug offset drug lost gener competit
potenti game changer growth rate includ
compani pipelin immuno-oncolog drug move
quickli clinic develop merck still face
gener competit older drug remicad zetia
vytorin next year howev believ
pipelin drug growth exist drug off-set
near-term gener headwind overal expect
improv margin near term overal sale
repres specialty-ori drug carri
strong price power need less market support
maintain uncertainti rate merck
medium overal larg base cash flow
divers inelast product portfolio rate merck
uncertainti medium view merck uncertainti
medium rather low due increas import
keytruda look well posit partli reduc
merck product divers cash flow scenario
analysi assum base-cas fair valu estim
bull case probabl bear
rel base case scenario analysi show
modest varianc henc medium uncertainti rate
key factor affect scenario analysi includ
degre success brand drug pipelin along
magnitud market pressur current market
drug within portfolio import driver
valuat keytruda cancer close quarter
sale come keytruda impact competit
new clinic data significantli affect import drug
merck
patent economi scale power intellectu
base buoy merck busi keep well shield
competit bedrock merck wide moat
patent protect continu keep competitor
bay compani strive introduc next
gener drug compani enorm cash
flow support power salesforc sell
current market drug also serv deterr
develop drug compani seek launch compet
opportun extern develop drug cash flow
also put compani rare posit support
approxim million need averag
bring new drug market power
merck research laboratori still hold
vast databas knowledg help compani
maintain leadership posit drug discoveri
develop also compani entrench
immuno-oncolog area strengthen
merck competit posit drug carri
strong price power area unmet medic need lastli
merck strong entrench vaccin add layer
competit protect intellectu properti cost
advantag firm large-scal product enabl
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
strateg focu toward unmet medic need
increas probabl success regulatori agenc
support stronger pharmaceut price power
payer fewer altern exist treatment area
face deterior moat trend past merck
competit advantag stabil patent protect
still shield major drug competit
compani develop enough new drug off-set
eventu patent loss pipelin side merck made
strateg shift acceler move focu
unmet medic need specialti care area
debilit lethal diseas strateg shift help
increas product fight back
follow three neg trend first post-vioxx era
food drug administr grown increasingli
risk-sensit primary-car diseas tend approv
safe drug drug highli need area
cancer second insur compani steadili
reduc coverag follow-on drug forc drug firm
push true innov reduc power
distribut network lastli govern
develop market increasingli use compar
effect program aggress push
price negoti respons challeng merck
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
okeytruda look best posit immuno-
advantag import indic first-lin non-
landscap buoy
oth growth merck high margin cancer drug
help expand compani overal oper
omerck support strong dividend yield look
secur base wide diversifi portfolio drug
ooutsid immuno oncolog merck need increas
number late-stag pipelin drug
owhil major patent loss behind
compani firm face gener competit
januvia potenti earli
oadvanc oncolog happen quickli
could caus disrupt merck lead growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
merck remain solid financi foot compani
close debt/capit strong cash flow
expect next sever year
strengthen balanc sheet howev merck signal
strong willing make acquisit histor
tend make sever bolt-on acquisit year
given merck made major acquisit sinc
schering-plough deal expect make
larger acquisit next two three year beyond
acquisit expect steadi futur dividend support
pay-out ratio close rel adjust
merck near-term risk larg center market accept
new drug like pharmaceut compani merck
face regulatori risk fda product delay
nonapprov could hurt stock also grow power
manag care price-sensit
addit merck face remain legal risk
vioxx major plaintiff particip
billion settlement holdout could ring major
addit settlement also litig risk remain
patient took one-tim blockbust fosamax
osteoporosi medicin link infrequ
seriou side effect lastli grow success
keytruda increas firm depend drug
growth could becom problemat side
effect show new therapi emerg quickli treat
cancer howev overal view merck uncertainti
medium given wide divers larg inelast drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
mr kenneth frazier ceo/chairman board/
repres date owner name posit common share held report holder issuer
american fund incom fund amer
new york mellon corp
share
fund
share
fund
ken frazier took ceo dick clark begin
appoint chairman board late
clark near retir age view
new leader continu merck past strategi
red flag shift leadership approach frazier
part success strategi guid clark frazier
almost two decad experi merck across
major divis posit well lead
compani also deserv much credit
success handl vioxx litig held
merck gener counsel posit major
litig merck board pack current retir
ceo lead quid pro quo compens
top execut
rate compani stewardship standard merck
shown reason use capit purchas
schering-plough fair price brought sever
import pipelin product includ keytruda
allow cost-cut opportun hand
billion acquisit cubist seem like stretch
make valuat work especi announc
sooner-than-expect patent loss key drug cubicin
merck heavi fund past decad
produc mix result sever import new drug
also mani failur howev compani shift
 focu toward area specialti care away
primari care continu support improv
product success keytruda exampl
new focu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
merck post strong aid keytruda vaccin
anim health drug stock look under-valued
merck report strong third-quart result ahead
capiq consensu expect plan
increas fair valu estim base robust result
continu view merck under-valued market
merck strength oncolog coupl solid traction
vaccin anim healthcar support firm wide
potenti
quarter total sale increas oper year
year led cancer drug keytruda
expect continu steadi gain drug keytruda first-
mover advantag largest market segment first-lin
lung cancer combin excel efficaci data
enabl drug gain lion share
competit data bristol opdivo yervoy
checkmat look potenti competit small
subseg market cant take chemotherapi
posit top-lin data announc
astra bristol studi poseidon checkmat
respect skeptic forthcom
detail data behind studi provid strong enough
data displac merck entrench also keytruda
new indic renal cancer adjuv melanoma
esophag cancer drive near-term growth
longer term expect favor data adjuv lung
cancer add signific growth potenti
beyond keytruda merck cancer drug lynparza
lenvima vaccin anim health product continu
post steadi gain continu next
sever year strong efficaci data behind cancer drug
robust demand china vaccin set solid growth
strong growth sale high-margin drug help
merck oper margin expect trend continu
model almost basi point margin
expans next five year
early-stag pipelin see encourag
data come oncolog platform believ next
major develop merck pipelin
keytruda adjuvant/neoadjuv use especi focus
lung cancer complet review outlook
immuno-oncolog drug earlier line usag pleas
see recent report immuno-oncolog drug adjuv
lung frontier strengthen moat
overview merck pipelin asset pleas see
remain secur innov counter price gener
headwind acceler
bristol lung cancer data favor checkmat
merck lead look secur sep
bristol-my report posit final data part one
chemotherapi first-lin non-smal cell lung cancer
nsclc dont expect signific chang
fair valu base data continu view bristol
under-valued acquisit celgen pipelin
fulli appreci market also continu
expect bristol focu oncolog drug drive strong
price power reinforc compani wide moat
cross-trial comparison drawback efficaci
bristol combin opdivo plu yervoy checkmat
doesnt look well posit merck keytruda-
plu chemotherapi howev patient
express approxim three quarter
patient adamantli use chemotherapi especi
due neutropenia anemia side effect issu bristol
combin offer best altern bristol
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
data low expressor less express
look competit trial design may limit
inclus sub-seg data label also data
squamou patient also
look competit
nevertheless merck control first-mov
advantag lead efficaci data believ keytruda
gain close first-lin metastat nsclc
market follow roch tecentriq bristol
opdivo includ yervoy one last remain
studi patient popul bristol checkmat
read first-half studi
includ chemotherapi prime help patient
aggress form diseas addit
control crossov import studi
believ part reason merck keytruda shown
rel strong overal surviv data relat limit
amount crossov chemotherapi arm
beyond first-lin nsclc expect next wave
import immuno-oncolog data address earli stage
cancer adjuv neoadjuv earli stage lung
cancer alon project close billion annual sale
probabl weight estim
probabl success earli treatment set
complet overview adjuvant/neoadjuv lung
market immuno oncolog drug pleas see report
titl immuno-oncolog drug adjuv lung
frontier strengthen moat
merck post impress support strong
keytruda vaccin sale jul
merck report strong second-quart result ahead
consensu expect expect slightli rais
fair valu estim base out-performance
continu view merck modestli under-valued
market fulli appreci compani immuno-
oncolog drug keytruda especi earlier line
therapi continu success data keytruda
potenti reinforc strong price power
drug merck strong posit immuno-
oncolog help reinforc compani wide moat
total sale increas oper quarter
driven keytruda vaccin well declin gener
pressur older drug expect continu strong
growth next three year merck annual
sever major patent loss older drug face
major patent loss potenti patent
loss diabet drug januvia gener pressur
like weigh growth sever year keytruda
remain earli part life-cycle signific
potenti market gain alreadi approv indic
well like new indic expect keytruda
posit well earlier-stag cancer recent
posit data neoadjuv triple-neg breast cancer
support keytruda use earlier line therapi
addit growth keytruda like
amplifi impact bottom line project higher
margin drug rel overal compani base
strong price power drug outsid keytruda
vaccin busi continu post excel growth
demand china help drive sale expect
human papillomaviru vaccin gardasil particularli well
posit growth intern market
merck make progress pipelin front
encourag data come oncolog platform
believ next major develop merck pipelin
keytruda adjuvant/neoadjuv use
especi focus lung cancer aggreg project
lung adjuvant/neoadjuv market expand
potenti close billion annual sale
probability-weight ad almost billion
project late-stag metastat set estim
probabl success early-treat set
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
base earli clinic data strength drug
late-stag set view merck roch best
posit adjuv set due first-mov
advantag upcom clinic data
month drug price overhaul remain key topic
washington result continu see industri
under-valued despit strong product increasingli
complet review outlook immuno-oncolog
drug earlier line usag pleas see recent
report immuno-oncolog drug adjuv lung
frontier strengthen moat overview
merck pipelin asset pleas see healthcar
secur
innov counter price gener
headwind acceler
senat financ committe chairman chuck grassley
democrat rank member ron wyden post
prescript drug price reduct act tuesday
although final bill need proceed
mark-up thursday get major vote full
committe could see chang proce
senat floor vote like mean bipartisan
agreement reach prior post share price
drug firm larg unmov news
think progress senat make less like
sever hh rule intern price benchmark
medicar part implement also mean
increasingli like legisl could hold price
increas extent make fair valu
estim chang news continu watch
updat senat follow thursday mark-up
hous like propos legisl
septemb caution possibl bipartisan
bill could pass senat fail hous
progress democrat will compromis
certain issu exampl medicar part direct
negoti includ pdpra regardless
expect overhang drug stock next sever
overal propos pdpra similar
discuss recent analysi rebat rule dead
signific benefit pdpra compar
rebat rule cost congression budget offic
cbo estim rebat rule would result
billion extra feder spend year
assum current rebat withheld contrast
cbo estim pdpra would save taxpay
billion year billion save
medicaid mostli increas maximum rebat
billion save medicar within medicar
save larg split part redesign
billion inflation-reb polici billion
would forc drugmak pay addit rebat drug
medicar part part price increas
exceed inflat cpi-u roughli annual
addit two medicar polici would help
beneficiari lower pocket cost premium
total billion year cbo also assum
inflation-reb provis would reduc drug cost
patient privat insur part redesign
would substanti effect patient
think unclear impact pdpra could
patient cover privat insur drugmak could
continu rais price privat market simpli pay
addit rebat necessari medicar
among highest-profil provis pdpra
propos cap medicar part part price increas
inflationari level begin excess price
increas would need return medicar form
rebat part expect larg
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
adjuvant/neoadjuv set strengthen moat
project lung adjuvant/neoadjuv market expand
potenti close billion annual sale
probability-weight ad almost billion
project late-stag metastat set estim
probabl success early-treat set
base earli clinic data strength drug
late-stag set view merck roch best
posit adjuv set due first-mov
advantag upcom clinic data
bristol astra earlier data
neoadjuv set skeptic
chemotherapi show strong enough efficaci
competit overal includ early- late-stag
set believ potenti immuno-oncolog drug
sale underappreci merck roch
see compani under-valued
complet report potenti immuno-
oncolog drug adjuv set focu
lung cancer indic pleas see report immuno-
oncolog drug adjuv lung frontier
impact even firm high exposur channel
biggest drug program take
larg price increas reimburs system alreadi
discourag instead reli high launch price
profit exampl among top drug medicar
part spend accord medicar drug
spend dashboard one saw averag annual price
increas
neulasta newer blockbust bristol opdivo
merck keytruda top annual price
increas part expect could
drug higher list price increas could
impact dashboard spend data indic averag
annual price increas top drug around
rebat rule dead suppli chain benefit drug firm
pressur estim drug firm exposur
anoth key part pdpra drug manufactur
perspect medicar part redesign could
implement would hit firm
expens drug hardest chang would cap out-
of-pocket cost previous patient paid drug cost
catastroph phase limit
patient enter catastroph coverag phase drug
firm would hook drug cost
elimin current coverag gap discount drug firm
pay cost coverag gap introduc
new respons higher spend level
discuss recent research see firm like gilead
hepat hiv treatment bristol/celgen cancer
therapi revlimid potenti expos peer
immuno-oncolog drug adjuv lung
frontier strengthen moat jun
innov immuno-oncolog drug support
econom moat merck roch bristol-my squibb
astrazeneca expect expans
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
